Hikma Pharmaceuticals: Jefferies upgrades to Hold with a target price of 1045p.
Morgan Stanley downgraded shares of credit checking service outfit Experian from 'overweight' to 'equalweight' on Monday, stating that a rapid expansion in consumer credit over the last four years and increasingly watchful eye from regulatory bodies could represent a headwind to volume growth.
Information services company Experian reported total revenue growth of 5% in its first quarter on Tuesday, driven primarily by a 17% surge in revenue in Latin America, as well as 8% growth in North America and 5% in the EMEA-Asia Pacific regions.
National Grid: HSBC upgrades to Buy with a target price of 1060p.
Abcam: Berenberg initiates at Buy with a target price of 1100p.
GlaxoSmithKline: Berenberg upgrades to Buy with a target price of 1885p.
Credit checking agency Experian was under the cosh on Friday as Deutsche Bank downgraded the stock to 'sell' from 'hold' and cut the price target to 1,460p from 1,560p.
Shire Pharmaceuticals: HSBC downgrades to Reduce with a target price of 4450p.
Jefferies downgraded credit checking company Experian to 'hold' from 'buy' and cut the price target to 1,550p from 1,670p following the company's preliminary full-year results on Thursday.
United Utilities: Deutsche Bank downgrades to Hold with a target price of 1050p.
Casting its critical eye over the larger UK business services groups, Morgan Stanley said Aggreko, Berendsen and Capita, instead recommending investors own DCC, AA, Experian and Rentokil.
AstraZeneca: UBS downgrades to Neutral with a target price of 5150p.
Experian has struck a deal to offload its email and online marketing to technology investor Vector Capital as part of a strategic review.
BT: Barclays reiterates overweight with a target price of 475p.
FTSE 100 information services company Experian reported a 4% rise in third-quarter organic revenue as it maintained its guidance for the full year.
Global information services company Experian issued its half-yearly financial report for the six months to 30 September on Wednesday, with 5% organic revenue growth to $2.24bn, which was in line with its board's target range.
N Brown: HSBC downgrades to hold with a target price of 205p.
Numis placed its rating and target price on Genus 'under review' on Thursday, after the animal genetics company reported its full year results.
Goldman Sachs upgraded Experian to 'buy' from 'neutral' and lifted the price target to 1,845p from 1,452p saying it now sees around 20% upside to the stock.
Experian: Barclays reiterates overweight with a target price of 1,550p.